GlassScriptPhysician profile
Shuba M Srinivasan
NPI 1497702328
$2,034.86
in general payments reported to CMS, 2019-2025
31 companies · $820 in 2025
The $820 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.17 · 2022: $448 · 2023: $176 · 2024: $522 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $411.35 | 2021-2025 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $149.71 | 2023-2025 | Lynparza, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $146.18 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $145.98 | 2022-2025 | Pomalyst, Opdivo, Reblozyl |
| Janssen Biotech, INC. | $132.58 | 2021-2025 | Tecvayli, Darzalex, Balversa |
| Incyte Corporation | $127.84 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $122.54 | 2022-2025 | Iclusig, Alunbrig, Vpriv |
| Abbvie INC. | $92.90 | 2025 | |
| Seagen INC. | $72.79 | 2021-2023 | Padcev |
| Pfizer INC. | $67.07 | 2024-2025 | |
| Gilead Sciences, INC. | $60.19 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $51.95 | 2024-2025 | |
| Daiichi Sankyo INC. | $49.47 | 2024 | Vanflyta |
| Genzyme Corporation | $40.15 | 2024 | |
| Servier Pharmaceuticals LLC | $30.05 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $28.47 | 2025 | Onpattro |
| Lilly USA, LLC | $27.49 | 2024 | Jaypirca, Retevmo, Verzenio |
| Immunocore Limited | $23.54 | 2024 | Kimmtrak |
| Novartis Pharmaceuticals Corporation | $23.27 | 2024 | |
| Stemline Therapeutics INC. | $22.90 | 2025 | Orserdu |
| Coherus Oncology, INC. | $22.72 | 2024 | |
| Taiho Oncology, INC. | $21.67 | 2024 | |
| Rigel Pharmaceuticals, INC. | $20.88 | 2024 | Rezlidhia, Tavalisse |
| Glaxosmithkline, LLC. | $20.78 | 2025 | Ojjaara |
| Genentech USA, INC. | $19.62 | 2025 | Itovebi |
| Regeneron Healthcare Solutions, INC. | $19.09 | 2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $18.61 | 2025 | Onivyde |
| Amgen INC. | $16.99 | 2022 | |
| Array Biopharma INC | $16.76 | 2025 | Mektovi, Xalkori, Lorbrena |
| Agios Pharmaceuticals, INC. | $16.17 | 2024 | |
| Mirati Therapeutics, INC. | $15.15 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuba Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.